Research Article
Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy
Table 3
Longitudinal changes in UMSARS scores.
| | Low-dose group | Medium- and high-dose groups | Overall value | Post hoc valuea |
| | UMSARS part I | | | | | | V1 (-1 month) | 20.00 (1.74) | 17.50 (1.23) | Group: 0.184 | 0.418 | | V7 (+1 month) | 19.67 (2.05) | 18.67 (1.45) | Time: 0.020 | 0.613 | | V8 (+3 months) | 26.67 (3.13) | 20.17 (2.21) | : 0.237 | 0.401 | | UMSARS part II | | | | | | V1 (-1 month) | 20.33 (1.73) | 18.00 (1.22) | Group: 0.165 | 0.458 | | V7 (+1 month) | 20.33 (2.95) | 17.50 (2.08) | Time: 0.049 | 0.458 | | V8 (+3 months) | 25.33 (2.39) | 18.33 (1.69) | : 0.131 | 0.144 | | Total UMSARS | | | | | | V1 (-1 month) | 43.00 (2.79) | 37.67 (1.97) | Group: 0.111 | 0.244 | | V7 (+1 month) | 42.67 (4.46) | 38.33 (3.16) | Time: 0.008 | 0.454 | | V8 (+3 months) | 55.33 (5.14) | 40.83 (3.64) | : 0.096 | 0.165 |
|
|
Values are expressed as estimated mean (standard error). Abbreviations: UMSARS: Unified Multiple System Atrophy Rating Scale; MSC: mesenchymal stem cell. aFalse discovery rate (FDR) adjusted value. |
